# Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
Canonical URL: https://biopharmsignal.com/news/COGT/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor
Ticker: COGT
Company: Cogent Biosciences
Source: Cogent Biosciences
Published: 2026-01-20 13:01 EST
Original Source URL: https://investors.cogentbio.com
## Summary

-  PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and ORR of 46% in patients who had received prior treatment with imatinib  -  Cogent is expected

## Article Body
-  PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and ORR of 46% in patients who had received prior treatment with imatinib  -  Cogent is expected
## Recent Company News
- 2026-05-30 12:00 EST — [Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting](https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-detailed-clinical-data-from-peak-phase-3-trial-with-bezuclastinib-in-combination-with-sunitinib-in-gastrointestinal-stromal-tumors-gist-at-2026-american-society-of-clinical-oncology-asco-annual-meeting) — Source: Cogent Biosciences
- 2026-05-28 12:00 EST — [Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST](https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-nda-with-priority-review-for-bezuclastinib-in-combination-with-sunitinib-for-patients-with-gist) — Source: Cogent Biosciences
- 2026-05-27 12:00 EST — [Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-participation-in-the-2026-jefferies-global-healthcare-conference) — Source: Cogent Biosciences
- 2026-05-12 13:30 EST — [Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress](https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-multiple-presentations-at-the-european-hematology-association-eha-2026-congress) — Source: Cogent Biosciences
- 2026-05-05 12:00 EST — [Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results](https://biopharmsignal.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-first-quarter-2026-financial-results) — Source: Cogent Biosciences
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)